Vestronidase alfa-vjbk

Vestronidase alfa-vjbk
Clinical data
Trade names Mepsevii
Synonyms Vestronidase alfa
Routes of
administration		 Injection
ATC code
Legal status
Legal status
Identifiers
CAS Number
UNII
KEGG
Chemical and physical data
Formula C3308H4996N874O940S16
Molar mass 72,562.49 g·mol−1

Vestronidase alfa-vjbk (trade name Mepsevii) is a drug for the treatment of Sly syndrome. It is a recombinant form of the human enzyme beta-glucuronidase. In the United States, it was approved in November 2017.[1]

References

  1. ↑ "FDA approves treatment for rare genetic enzyme disorder" (Press release). Food and Drug Administration.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.